Stocktoria
Fulgent Genetics, Inc. FLGT
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2016-09-28
Fulgent Genetics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 40.6% | 37.8% | 36.1% | 59.3% | 78.3% |
| Operating margin | -28.2% | -26.1% | -67.6% | 28.8% | 68.1% |
| Net margin | -18.8% | -15.1% | -58.0% | 23.2% | 51.1% |
| FCF margin | -38.5% | -6.8% | 1.7% | 37.9% | 51.9% |
| Return on assets | -5.0% | -3.5% | -13.6% | 10.3% | 39.7% |
| Return on equity | -5.4% | -3.8% | -14.8% | 11.3% | 43.5% |
| Current ratio | 6.48 | 4.85 | 6.96 | 7.13 | 5.81 |
| Revenue growth | 13.8% | -2.0% | -53.3% | -37.6% | 135.4% |
Source: SEC EDGAR filings · CIK 0001674930 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.